Abbott pays $310M for stent developer

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Abbott plans to buy IDEV Technologies for $310 million, a move that will expand Abbott’s portfolio of stents for treating peripheral artery disease.

Webster, Texas-based IDEV Technologies develops endovascular technologies such as the SUPERA Veritas, a self-expanding nitinol stent system that received CE mark as a treament for PAD and was launched in Europe in 2010. In the U.S., the stent system was cleared in 2011 for palliative treatment of biliary strictures produced by malignant neoplasms. The FDA is reviewing the technology under Premarket Approval Application for treatment of the superficial femoral artery.

Abbott said it would purchase IDEV Technologies for $310 million net of cash and debt. The deal is expected close by the end of this year. Abbott is based in Abbott Park, Ill.

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."